Conferences
Meet in person with Christopher Kata during CPHI in Frankfurt, on November 1st to 3rd. If you’re attending be sure to reach out to Christopher to schedule a one on meeting! Each year CPHI unites more than 100,000 pharmaceutical professionals through exhibitions, conferences and online communities to network, identify business opportunities and expand the global…
Read More
Christopher Kata is once again attending the CRAC – Future Considerations for Conducting Clinical Trials November 17th at the Markland Wood Golf Club. If you’re attending be sure to reach out to Christopher to schedule a one on meeting or search him out at the meeting! Christopher will be delivering a presentation titled “How To…
Read More
Christopher Kata is once again attending the CTO 2022 – Clinical Trials Ontario Conference on November 10th and 11th at the Hilton Toronto, 145 Richmond Street West, Toronto, ON, M5H 2L2. If you’re attending be sure to reach out to Christopher to schedule a one on meeting or search him out at the meeting! The CTO…
Read More
Christopher Kata is once again attending this years 24th Annual SocalBio Conference October 6th to 7th at the The West Long Beach. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or search him out at the meeting! Christopher Kata, Director of Sales & Marketing905 [email protected] When:…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass., Sept. 22, 2022 /PRNewswire/ — Phio Pharmaceuticals Corp. ( Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its research partner, Helmholtz Munich, presented preclinical data showing that Phio’s lead clinical product PH-762, an…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years SCDM meeting on September 13th through the 16th in booth #400. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #400 at your convenience! Drop by for a chance to win…
Read More
Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of ROS1-selective inhibitor NVL-520 Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 5, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new preclinical data…
Read More
– Oral presentation of new preclinical data at American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting – Excerpt from the Press Release: SAN DIEGO, May 19, 2022 /PRNewswire/ — Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with severe neuromuscular and neurodegenerative diseases, today announced the presentation of new preclinical data on its…
Read More
CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment Additional non-clinical data demonstrates combination benefit across a diverse range of syngeneic models with differential sensitivity to checkpoint inhibition Anti-tumor activity correlates with increases in proliferating CD4+ and CD8+ T-cells as well as the NK…
Read More
Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversible stem cell damage Aileron’s…
Read More- « Previous
- 1
- 2
- 3
- 4
- Next »